BG106407A - Лечение на мигрена чрез приложение на алфа-липоева киселина или нейни прозводни - Google Patents

Лечение на мигрена чрез приложение на алфа-липоева киселина или нейни прозводни

Info

Publication number
BG106407A
BG106407A BG106407A BG10640702A BG106407A BG 106407 A BG106407 A BG 106407A BG 106407 A BG106407 A BG 106407A BG 10640702 A BG10640702 A BG 10640702A BG 106407 A BG106407 A BG 106407A
Authority
BG
Bulgaria
Prior art keywords
treatment
lipoic acid
alpha
migraine
administration
Prior art date
Application number
BG106407A
Other languages
English (en)
Other versions
BG65735B1 (bg
Inventor
Jean Schoenen
Juergen Engel
Klaus Wessel
Manfred Peukert
Michael Lobisch
Harald Borbe
Original Assignee
VIATRIS Gmbh & Co.KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIATRIS Gmbh & Co.KG filed Critical VIATRIS Gmbh & Co.KG
Publication of BG106407A publication Critical patent/BG106407A/bg
Publication of BG65735B1 publication Critical patent/BG65735B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до приложение на рацемична алфа-липоева киселина или нейни енантиомери, илинейни фармацевтично приемливи соли, амиди, естериили тиоестери в редуцирана или окислена форма като активно средство за профилактика или лечение на остра или хронична мигрена.
BG106407A 1999-08-30 2002-02-12 Приложение на алфа-липоева киселина или нейни прозводни за лечение на мигрена BG65735B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (2)

Publication Number Publication Date
BG106407A true BG106407A (bg) 2002-10-31
BG65735B1 BG65735B1 (bg) 2009-09-30

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106407A BG65735B1 (bg) 1999-08-30 2002-02-12 Приложение на алфа-липоева киселина или нейни прозводни за лечение на мигрена

Country Status (32)

Country Link
US (1) US6251935B1 (bg)
EP (1) EP1207878B1 (bg)
JP (1) JP4773015B2 (bg)
KR (1) KR100624215B1 (bg)
CN (1) CN1170535C (bg)
AT (1) ATE232725T1 (bg)
AU (1) AU781505B2 (bg)
BG (1) BG65735B1 (bg)
BR (1) BR0013651A (bg)
CA (1) CA2382548C (bg)
CZ (1) CZ301789B6 (bg)
DE (2) DE19941217A1 (bg)
DK (1) DK1207878T3 (bg)
EE (1) EE04869B1 (bg)
ES (1) ES2190985T3 (bg)
HK (1) HK1046637A1 (bg)
HR (1) HRP20020168A2 (bg)
HU (1) HU229603B1 (bg)
IL (2) IL148068A0 (bg)
IS (1) IS2214B (bg)
MX (1) MXPA02002246A (bg)
NO (1) NO328692B1 (bg)
NZ (1) NZ517276A (bg)
PL (1) PL200928B1 (bg)
PT (1) PT1207878E (bg)
RS (1) RS50139B (bg)
RU (1) RU2232577C2 (bg)
SK (1) SK286260B6 (bg)
TR (1) TR200200461T2 (bg)
UA (1) UA71031C2 (bg)
WO (1) WO2001015693A2 (bg)
ZA (1) ZA200201637B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900338B1 (en) * 1998-11-25 2005-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
KR20120025519A (ko) 2009-05-15 2012-03-15 레드엑스 파마 리미티드 산화환원 약물 유도체
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
ES2115589T3 (es) * 1989-11-09 1998-07-01 Asta Medica Ag Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
CZ96798A3 (cs) * 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
JP2002510604A (ja) * 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
JP4773015B2 (ja) 2011-09-14
EP1207878A2 (de) 2002-05-29
HUP0203025A3 (en) 2004-12-28
WO2001015693A3 (de) 2001-12-20
EP1207878B1 (de) 2003-02-19
NO20020917D0 (no) 2002-02-25
HUP0203025A2 (hu) 2002-12-28
CZ301789B6 (cs) 2010-06-23
TR200200461T2 (tr) 2002-08-21
DK1207878T3 (da) 2003-06-16
ES2190985T3 (es) 2003-09-01
US6251935B1 (en) 2001-06-26
IL148068A (en) 2007-06-03
WO2001015693A2 (de) 2001-03-08
EE04869B1 (et) 2007-08-15
CA2382548C (en) 2007-07-03
PT1207878E (pt) 2003-07-31
DE50001301D1 (de) 2003-03-27
ATE232725T1 (de) 2003-03-15
IS2214B (is) 2007-03-15
PL352741A1 (en) 2003-09-08
DE19941217A1 (de) 2001-03-15
BG65735B1 (bg) 2009-09-30
PL200928B1 (pl) 2009-02-27
HK1046637A1 (en) 2003-01-24
HRP20020168A2 (en) 2003-06-30
CA2382548A1 (en) 2001-03-08
BR0013651A (pt) 2002-05-07
IL148068A0 (en) 2002-09-12
CN1170535C (zh) 2004-10-13
KR20020060168A (ko) 2002-07-16
NZ517276A (en) 2004-06-25
IS6284A (is) 2002-02-26
RS50139B (sr) 2009-03-25
MXPA02002246A (es) 2003-08-20
CN1371280A (zh) 2002-09-25
NO20020917L (no) 2002-02-25
KR100624215B1 (ko) 2006-09-18
CZ2002655A3 (cs) 2002-07-17
YU15002A (sh) 2005-03-15
AU7279900A (en) 2001-03-26
SK2902002A3 (en) 2002-09-10
SK286260B6 (sk) 2008-06-06
NO328692B1 (no) 2010-04-26
AU781505B2 (en) 2005-05-26
HU229603B1 (en) 2014-02-28
UA71031C2 (uk) 2004-11-15
RU2232577C2 (ru) 2004-07-20
EE200200098A (et) 2003-04-15
JP2003508438A (ja) 2003-03-04
ZA200201637B (en) 2003-01-29

Similar Documents

Publication Publication Date Title
MY130441A (en) Solutions containing epinastin
PT1452524E (pt) Derivado de 2-oxo-1-pirrolidina e suas utilizações farmacêuticas
IL195055A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
BG106407A (bg) Лечение на мигрена чрез приложение на алфа-липоева киселина или нейни прозводни
MXPA02012182A (es) Medicamentos para la terapia de demencias.
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
AU695907B2 (en) Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
AR026435A1 (es) Procedimiento para la administracion simplificada del acido alfa-lipoico, o de derivados del mismo y el procedimiento para preparar la composicionfarmaceutica o nutricional de aplicacion en dicho metodo
WO2000003699A3 (de) Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung